SciELO - Scientific Electronic Library Online

vol.26 issue1Acuabio 1, an enhancer of the immune system in Litopennaeus vannamei shrimpsNeuroprotective effect of the systemic administration of MK-801 on the pedunculopontine nucleus of hemiparkinsonian rats author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Biotecnología Aplicada

On-line version ISSN 1027-2852


GONZALEZ, Nery et al. Epidermal growth factor in the treatment of radiogenic proctitis. Biotecnol Apl [online]. 2009, vol.26, n.1, pp.49-52. ISSN 1027-2852.

Radiogenic proctitis is a frequent complication of therapeutic radiation at the pelvic region. The aim of this study was to determine the efficacy of the epidermal growth factor (EGF) in treating patients with proctitis as a complication of radiotherapy of gynecological tumors. A phase II, placebo-controlled, randomized, double blind clinical trial was carried out. The treatment groups were: A) a solution of human recombinant epidermal growth factor (10 µg/ ml) in carboxymethyl cellulose or B) placebo (carboxymethylcellulose solution alone); the treatment was administered as a retention enema (20 mL) twice a day after bowel movement for 6 months. We included women of 18-75 years of age with proctitis as a complication of an ionizing radiation treatment of gynecological malignant tumors, confirmed by endoscopy, who gave their consent to participate. Thirty-seven patients were included. The basic demographic variables and were homogeneous among groups, which were comparable. There were more responses in group A (EGF) than in the control (placebo), but the difference was not statistically significant. Considering only those patients who completed the treatment, the difference in response was greater with EGF (86% vs 60%). The symptoms disappeared more rapidly in the group treatedwith EGF (p=0.027 and p=0.016, for bleeding and tenesmus, respectively). The product under study was well tolerated. Although there are signs of improvement in some symptoms, the sample was too small to demonstrate the effectiveness of Hebervis in the treatment of proctitis.

Keywords : EGF; proctitis; radiotherapy; clinical trial.

        · abstract in Spanish     · text in English     · English ( pdf )